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Abstract
Introduction: Only limited information exists on the pharmacokinetics of prolonged (> 24 hours) and high-dose
dexmedetomidine infusions in critically ill patients. The aim of this study was to characterize the pharmacokinetics
of long dexmedetomidine infusions and to assess the dose linearity of high doses. Additionally, we wanted to
quantify for the first time in humans the concentrations of H-3, a practically inactive metabolite of
dexmedetomidine.
Methods: Thirteen intensive care patients with mean age of 57 years and Simplified Acute Physiology Score (SAPS)
II score of 45 were included in the study. Dexmedetomidine infusion was commenced by using a constant
infusion rate for the first 12 hours. After the first 12 hours, the infusion rate of dexmedetomidine was titrated
between 0.1 and 2.5 μg/kg/h by using predefined dose levels to maintain sedation in the range of 0 to -3 on the
Richmond Agitation-Sedation Scale. Dexmedetomidine was continued as long as required to a maximum of 14
days. Plasma dexmedetomidine and H-3 metabolite concentrations were measured, and pharmacokinetic variables
were calculated with standard noncompartmental methods. Safety and tolerability were assessed by adverse
events, cardiovascular signs, and laboratory tests.
Results: The following geometric mean values (coefficient of variation) were calculated: length of infusion, 92 hours
(117%); dexmedetomidine clearance, 39.7 L/h (41%); elimination half-life, 3.7 hours (38%); and volume of distribution
during the elimination phase, 223 L (35%). Altogether, 116 steady-state concentrations were found in 12 subjects. The
geometric mean value for clearance at steady state was 53.1 L/h (55%). A statistically significant linear relation (r
2 = 0.95;
P < 0.001) was found between the areas under the dexmedetomidine plasma concentration-time curves and
cumulative doses of dexmedetomidine. The elimination half-life of H-3 was 9.1 hours (37%). The ratio of AUC0-∞ of H-3
metabolite to that of dexmedetomidine was 1.47 (105%), ranging from 0.29 to 4.4. The ratio was not statistically
significantly related to the total dose of dexmedetomidine or the duration of the infusion.
Conclusions: The results suggest linear pharmacokinetics of dexmedetomidine up to the dose of 2.5 μg/kg/h.
Despite the high dose and prolonged infusions, safety findings were as expected for dexmedetomidine and the
patient population.
Trial Registration: ClinicalTrials.gov: NCT00747721
Introduction
Many patients treated in intensive care units (ICUs)
require sedation and analgesia to tolerate the tracheal
tube, mechanical ventilation, and other intensive care
procedures. However, commonly used sedatives like
propofol, benzodiazepines, and opioids also have poten-
tial adverse effects that may increase morbidity and pro-
long the patients’ clinical course [1]. Consequently, new
drugs, with alternate mechanisms of action, have been
developed for sedation of ICU patients.
Dexmedetomidine is a highly selective and potent a-2
adrenoreceptor agonist indicated for procedural and
ICU sedation. It is quickly distributed into tissues with a
distribution half-life of approximately 6 minutes. It is
* Correspondence: tiirola@utu.fi
1Department of Anaesthesiology, Intensive Care, Emergency Care and Pain
Medicine, University of Turku and Turku University Hospital, PO Box 52, FI-
20521 Turku, Finland
Full list of author information is available at the end of the article
Iirola et al. Critical Care 2011, 15:R257
http://ccforum.com/content/15/5/R257
© 2011 Iirola et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.metabolized in the liver to practically inactive products,
mainly glucuronides, with a mean elimination half-life of
2 to 2.5 hours [2], with an extraction ratio of 0.71 [3].
Direct N-glucuronidation accounts for one third of the
metabolism of dexmedetomidine [2]. Additionally, the
drug is metabolized by multiple cytochrome P450
enzymes, especially CYP2A6, but also CYP1A2,
CYP2C19, CYP2D6, and CYP2E1 [4]. Approximately
90% of an administered human drug dose is excreted as
metabolites in the urine, and 10%, in the feces [2]. As
well as offering sedation and anxiolysis, dexmedetomi-
dine has moderate analgesic qualities, and it reduces the
stress response to noxious stimuli [5]. Although the
pharmacokinetics of dexmedetomidine have been stu-
died previously during short-term use in an ICU setting
[6], to our knowledge, only limited information exists
on the pharmacokinetics of prolonged (> 24 hours) and
high-dose dexmedetomidine infusions in critically ill
patients. This study was designed to characterize the
pharmacokinetics of long dexmedetomidine infusions
and specifically to assess the dose linearity of high
doses. We also quantified for the first time in humans
the concentrations of the previously poorly characterized
H-3 metabolite of dexmedetomidine (Figure 1). Because
the structure of the H-3 metabolite has been unknown,
no bioanalytic methods have been available until quite
recently. The metabolite has practically no relevant
pharmacologic activity (unpublished data).
Materials and methods
Patients
This study (EudraCT number 2008-001646-10/Clinical-
Trials.gov identifier NCT00747721) was conducted in a
24-bed mixed intensive care unit of a tertiary teaching
hospital in Finland from September 2008 to February
2009. It was approved by the Ethics Committee of the
Hospital District of Southwest Finland and by the Fin-
nish Medicines Agency. It was conducted according to
the revised Declaration of Helsinki of the World Medi-
cal Association and ICH GCP guidelines for good clini-
cal trial practice with external study monitoring.
On empiric grounds, it was planned to recruit
between 12 and 20 patients so that at least six of the
patients would have a minimum duration of 5 days of
dexmedetomidine infusion. In total, 13 patients were
enrolled. A written informed consent was obtained from
the legal representatives of potential study subjects, and
the decision for entry was made according to the inclu-
sion and exclusion criteria. Patients older than 18 years,
needing light to moderate sedation (0 to -3 on the Rich-
mond Agitation-Sedation Scale (RASS) [7]) for at least
24 hours to tolerate the ventilator, were eligible for the
study. Patients having an acute severe intracranial or
spinal neurologic disorder, uncompensated circulatory
failure (mean arterial pressure < 55 mm Hg despite
vasopressors and inotropes), severe bradycardia, second-
or third-degree atrioventricular block, severe hepatic
impairment, positive pregnancy test, needing continuous
muscle relaxation, using centrally acting a-2 agonists or
antagonists, or having an allergy to dexmedetomidine or
any excipients of the study treatment were not consid-
ered eligible for the study.
Study treatment
No loading dose was administered, but a constant intra-
venous infusion of dexmedetomidine was given for an
initial period of 12 hours. The starting dose was based
on our previous experiences with sedative agents in the
ICU and determined by the pre-study dose of propofol
or midazolam: a dose of 0.1, 0.2, 0.45, or 0.7 μg/kg/h of
dexmedetomidine was considered to be equivalent to <
0.3, 0.3 to 0.79, 0.8 to 1.59, and > 1.6 mg/kg/h of propo-
fol or < 0.03, 0.03 to 0.06, 0.06 to 0.09, and > 0.09 mg/
kg/h of midazolam, respectively. Downward titration
was allowed in case of oversedation or an adverse event.
After the 12-hour constant-rate infusion, the infusion
rate of dexmedetomidine was titrated as needed between
a minimum of 0.1 and a maximum of 2.5 μg/kg/h by
titrating the dose stepwise upward or downward to
maintain sedation in range of 0 to -3 by using the
RASS. Only predefined dose levels of 0.1, 0.2, 0.45, 0.7,
0.95, 1.2, 1.4, 1.7, 2.1, and 2.5 μg/kg/h of dexmedetomi-
dine were used. Propofol or midazolam was discontin-
ued on commencement of dexmedetomidine infusion.
However, the patient was allowed to be given additional
sedation with the previous sedative agent (propofol or
midazolam) if the target RASS of 0 to -3 was not
achieved with dexmedetomidine.
Dexmedetomidine was continued as long as required
to a maximum of 14 days. When the decision to discon-
tinue the treatment was taken, it had to be stopped
abruptly and not to be commenced again. If further
sedation was required after dexmedetomidine had been
stopped, standard-of-care sedation was instituted. After
completion of the study treatment, study subjects were
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Figure 1 Structural formula of H-3 metabolite.
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Page 2 of 10monitored for 48 hours and contacted by telephone or
visit 31 and 45 days after starting the study treatment to
record possible adverse events and concomitant treat-
ments related to serious adverse events.
Concomitant treatments
Oxycodone and fentanyl were used for the treatment of
pain. The co-administration of centrally acting a-2 ago-
nists or antagonists was prohibited. All concomitant
treatments from screening to the end of the 48-hour fol-
low-up period were recorded.
Blood sampling
Arterial or central venous blood samples for dexmedeto-
midine and H-3 metabolite concentration measurements
were collected before and 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8,
and 12 hours after starting study treatment, 3 times per
day in the morning, afternoon, and evening of the fol-
lowing treatment days. Additional samples were drawn
immediately before and 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 9,
12, 15, 18, 24, 36, and 48 hours after stopping study
treatment. In case of hemodiafiltration, a venous blood
sample was taken before commencing filtration. There-
after, concomitant venous samples from the afferent and
efferent limbs of the filter circuit were withdrawn at 2,
4, 6, and 8 hours.
Sample handling
The 3-ml blood samples were drawn into chilled EDTA
tubes, and they were immediately put into crushed ice.
The samples were delivered in a few minutes to an
accredited laboratory, where they were stored appropri-
ately and centrifuged at 4°C within 3 hours after sam-
pling. For logistic reasons, the plasma was frozen
immediately after centrifugation at -20°C, and the sam-
ples were transferred to -70°C within 72 hours, where
they were stored until the analysis.
Dexmedetomidine and H-3 metabolite analysis
Concentrations of dexmedetomidine and H-3 metabolite
in EDTA plasma samples were determined with high-
performance liquid chromatography and mass spectro-
metric detection (HPLC-MS/MS; Shimadzu Prominence
HPLC, Kyoto, Japan) connected to an AB Sciex API4000
mass spectrometer (Toronto, Ontario, Canada), as pre-
viously described [8]. The mobile phase was 0.1% formic
acid in a mixture of 1:1:1 (vol/vol/vol) methanol/aceto-
nitrile/water. The lower limit of quantification was 0.02
ng/ml. The within- and between-run precision of the
assay (coefficient of variation) was within 7.5% in the
relevant concentration range. The data from the HPLC-
MS/MS analyses were collected by using Analyst 1.4.1
software (AB Sciex, Toronto, Ontario, Canada). The cal-
culations were based on peak area ratios of the analyte
and the internal standard. Deuterated medetomidine
(Orion Pharma, Espoo, Finland) and H-3 metabolite
(Orion Pharma) were used as the internal standards.
Pharmacokinetic analysis
The pharmacokinetics of dexmedetomidine and the H-3
metabolite were characterized by using noncompart-
mental methods with the pharmacokinetic program
WinNonlin 5.0.1 Professional (Pharsight Corporation,
Mountain View, CA, USA). For each subject, the term-
inal log-linear phase of the plasma drug concentration-
time curve for postinfusion data was identified visually,
and the elimination rate constant (ke) was determined
by regression analysis. The elimination half-life (t1/2)
w a sc a l c u l a t e df r o mt h ee q u a t i o nt1/2 =l n2 / ke. Plasma
clearance (Cl) and volume of distribution during elimi-
nation (V) were calculated by the use of standard non-
compartmental methods based on statistical moment
theory. The areas under the drug plasma concentration-
time curves (AUC0-∞) were estimated by using the tra-
pezoidal method with extrapolation to infinity. In
patients lacking the data during the 48-hour follow-up
period after stopping dexmedetomidine infusion, the
AUC0-∞ was estimated by using the mean ke value of
the other subjects, as follows: AUC0-∞ = AUC0-last + last
measured concentration/mean ke. During the continuous
infusion of dexmedetomidine, we estimated repetitively
dexmedetomidine Clss from Clss =I ss/Css,w h e r eI ss =
infusion rate at steady state and Css = concentration at
steady state. It was estimated that steady state was
reached after a constant infusion of 15 hours, which
clearly exceeds 3.3 half-lives, generally assumed to be
necessary for reaching steady state during dexmedetomi-
dine infusion [2,9].
Analysis of sedation
Depth of sedation was assessed at approximately at the
same time each day during the treatment and the 48-
hour follow-up period by using the RASS.
Assessment of safety and tolerability
Adverse events, heart rate (HR), mean arterial blood
pressure (MAP), 12-lead ECG, continuous ECG, and
safety laboratory assessmen t sw e r eu s e da ss a f e t ya n d
tolerability variables. Adverse events and serious adverse
events were defined as suggested by the European Medi-
cines Agency [10]. In addition to clinically significant
changes in vital signs, sustained MAP lower than 50
mm Hg or higher than 125 mm Hg and HR lower than
50 beats/min or higher than 120 beats/min (provided
change in HR was ≥ 10%) were reported as adverse
events.
Cardiac rhythm, including arrhythmias and AV blocks,
was followed continuously and recorded daily. Any
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report were reported as adverse events. In addition, any
changes indicative of myocardial ischemia were reported
as adverse events.
Blood samples were collected for complete blood
count, glucose, urea, creatinine, albumin, alanine amino-
transferase, aspartate aminotransferase, g-glutamyl trans-
ferase, alkaline phosphatase, bilirubin, lactate
dehydrogenase, troponin T, total protein, triglycerides,
total cholesterol, sodium, potassium, calcium, chloride,
and cortisol. Changes in the laboratory parameters
resulting to a new diagnosis or a change in the treat-
ment were considered to be clinically significant and
were reported as adverse events. In addition, elevated
troponin T indicative of myocardial ischemia, liver
enzymes > 5 times the upper limit of normal, and biliru-
bin > 5 times the upper limit of normal were reported
as adverse events.
Statistical methods
All analyses and tabulations were performed in treated
subjects and are presented as geometric mean (coefficient
of variation), unless otherwise indicated. The relations of
the dexmedetomidine Cl and creatinine, and the total dex-
medetomidine dose, and the dexmedetomidine AUC0-∞
were evaluated by using the linear regression model.
Evaluation of effects of length of infusion and infusion
rate to dexmedetomidine clearance was done by using
analysis of covariance. The effect of baseline patient fac-
tors on the pharmacokinetics of dexmedetomidine was
tabulated by using descriptive statistics and was analyzed
by patient factors. Continuous patient factors were
dichotomized in descriptive tabulations by using the
median as a cut-point. These patient factors included
gender, age, Simplified Acute Physiology Score (SAPS II)
[11] at screening, and baseline heart rate, blood pressure,
creatinine, and creatinine clearance, calculated by using
the Cockcroft-Gault formula [12]. The analysis-of-var-
iance model (for categoric factors) and analysis of co-var-
iance (for continuous factors) were used to assess
statistical significance. No multiplicity adjustments were
done. Statistical analyses were performed by using SAS
software version 9.2 (SAS Institute Inc., Cary, NC, USA),
and significance was reported at a P value of 0.05 or less.
Results
Patient population
In total, 13 Caucasian subjects were screened and
included in the study (Table 1). No subjects discontin-
ued the study prematurely, but three subjects were with-
drawn from the study treatment because they died
during the study. The deaths were not related to the use
of dexmedetomidine. The study population consisted of
both male and female subjects, with the mean age of
57.4 years (range, 18 to 82 years). The reason for ICU
admission was medical in five, surgical in five, and
trauma in three patients, and their mean SAPS II score
was 44.8 (31.9%).
Concomitant treatments
All patients had prior pharmacologic treatments and
were already sedated before the start of dexmedetomi-
dine infusion. Most commonly used treatments during
dexmedetomidine infusion were short-acting insulin (13
of 13), oxycodone (13 of 13), noradrenaline (13 of 13),
rescue propofol (12 of 13), enoxaparin (12 of 13),
esomeprazole (12 of 13), and b-lactam antibacterials (11
of 13). None of the drugs used is known to be a strong
inhibitor or inducer of the enzymes relevant in the phar-
macokinetics of dexmedetomidine.
Dexmedetomidine pharmacokinetics
The observed dexmedetomidine concentrations varied
widely between the patients. The individual
Table 1 Characteristics of 13 intensive care patients
Patient number
Variable 1 2 3 4 5 6 7 8 9 10 11 12 13 Mean CV
(%)
Weight (kg) 80 90 120 56 85 90 60 60 85 105 110 80 100 86.2 22.8
Age (years) 75 69 50 18 59 53 82 77 74 42 57 56 35 57.4 32.1
SAPS II 48 68 38 34 39 40 47 47 73 42 55 29 22 44.8 31.9
Bilirubin (μmol/L) 40 11 8 14 4 109 10 5 91 17 - 12 15 16.1
a 138
Creatinine (μmol/L) 79 179 186 45 163 112 175 44 156 97 - 77 72 103
a 56.2
Day from ICU admission 1.1 1.1 1.1 2.7 1.1 1.1 3.6 2.5 1.8 1.3 1.5 4.9 0.9 1.6
a 58.3
Vasopressors Yes Yes Yes Yes Yes No Yes Yes Yes Yes Yes Yes Yes
Midazolam (M) or propofol (P) rate (mg/
kg/h)
- 0.1
(M)
2.3
(P)
3.8
(P)
1.9
(P)
- 3.2
(P)
1.3
(P)
1.7
(P)
0.1 (P)
b
2.9
(P)
0.1 (P)
b
1.5 (P)
b
Bilirubin and creatinine values refer to the highest value during dexmedetomidine infusion. Day from ICU admission refers to the day dexmedetomidine infusion
was commenced. Vasopressors indicate whether the patient received vasoactive drugs before dexmedetomidine infusion. Midazolam or propofol rate, infusion
rate before the start of dexmedetomidine infusion; CV, coefficient of variation; SAPS II, Simplified Acute Physiology Score;
ageometric mean (backtransformed
mean of the values on the logarithmic scale);
bintravenous boluses.
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curves during the entire study period are shown in Fig-
ure 2. The corresponding curves during the initial com-
mencement and after the discontinuation of the infusion
are depicted in Figure 3.
The values of the pharmacokinetic variables are shown
in Table 2. The geometric mean value of dexmedetomi-
dine clearance was 39.7 L/h (40.9%). In the 10 patients
with complete data sets, the geometric mean values for
t1/2, Cl, and V during the elimination phase were 3.7 h
(38.1%), 41.4 L/h (46.7%) and 223.3 L (35.3%),
respectively.
There were 116 steady-state concentrations in 12 sub-
jects (Figure 4). Fifteen of the steady-state concentra-
tions were reached during an infusion rate of 0.1 μg/kg/
h, one during an infusion rate of 0.4 μg/kg/h, three dur-
ing an infusion rate of 0.7 μg/kg/h, one during an infu-
sion rate of 2.1 μg/kg/h, and 96 during an infusion rate
of 2.5 μg/kg/h. The geometric mean value for Clss was
53.1 L/h (54.8%; range, 8.4 to 115 L/h). A statistically
significant relation was found between dexmedetomidine
Clss and length of infusion (P = 0.0007) and infusion
rate (P < 0.0001) in univariate analysis. In multivariate
analysis, where both length of infusion and infusion rate
were included in the model, only the infusion rate was
statistically significant (P < 0.001). The interaction
between the length of the infusion and the infusion rate
was not statistically significant.
The AUC0-∞ of dexmedetomidine plotted against the
total cumulative dose is shown in Figure 5. A statisti-
cally significant linear relation (r
2 = 0.95; P < 0.001) was
found between AUC0-∞ and the cumulative dose of
dexmedetomidine.
The dexmedetomidine Cl was higher (P = 0.006) in
patients with low baseline SAPS II scores (< 42) com-
pared with subjects with high scores (≥ 42). The corre-
sponding values for geometric mean Cl were 57.6 L/h
(24.7%) and 33.2 L/h (43.5%), respectively. In subjects
with low baseline SAPSII scores (< 42), dexmedetomi-
dine t1/2 was shorter (P = 0.036) compared with subjects
with higher baseline SAPSII scores (≥ 42), with geo-
metric mean values being 2.9 hours (39.9%) and 4.4
hours (27.6%), respectively. Dexmedetomidine Cl and
creatinine clearance showed a linear correlation at base-
line (P = 0.026). Other patient factors did not signifi-
cantly affect clearance.
H-3 metabolite pharmacokinetics
The geometric mean value for t1/2 of H-3 during the
elimination phase was 9.1 hours (37.0%; n = 10). The
geometric mean ratio of AUC0-∞ of H-3 metabolite to
that of dexmedetomidine was 1.47 (105%), ranging
from 0.29 to 4.4. The ratio was not statistically signif-
icantly related to the total dose of dexmedetomidine
(P = 0.528) or the duration of the infusion (P =
0.872).
Effect of hemodiafiltration
Hemodiafiltration was performed for one subject who
was admitted with acute on chronic renal failure and
had renal-replacement therapy during the current
admission. Based on simultaneously measured drug con-
centrations in the afferent and efferent limbs of the filter
circuit, no evidence was found in this single subject that
dexmedetomidine or H-3 metabolite was extracted from
plasma by hemodiafiltration (data not shown).
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Figure 2 Dexmedetomidine concentration profiles of the 13 patients during the infusion and the 48-hour follow-up. The 48-hour
follow-up was not reached in the three patients who were withdrawn from the study treatment and died of adverse events. Conc,
concentration.
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Altogether 88 RASS values were recorded in the 13
patients. In four of the 88 recordings (4.5%), underseda-
tion was discovered, when the patients were treated
according to the protocol (dexmedetomidine infusion
enhanced with propofol infusion or boluses). All but
one patient (12 of 13) needed at least one bolus dose of
propofol to keep the RASS value in the target zone, and
the median amount of propofol was 1,869 mg/day
(range, 79 to 8,505 mg). The number of patients overse-
dated, on target, and undersedated during the study is
shown in Figure 6.
Safety
In total, 53 adverse events were reported in 12 subjects
after the start of the study treatment. The most com-
mon adverse events were tachycardia (nine events),
hypotension (five events), and hypertension (four
events). Four of the adverse events were assessed as
being related to the study treatment: three episodes of
bradycardia and one episode of first-degree AV block.
These four adverse events all resolved, with the brady-
cardias requiring dexmedetomidine dose reduction, and,
in two cases, administration of atropine and glycopyrro-
late. Most of the adverse events were recorded in the
highest dose range of 1.4 to 2.5 μg/kg/h, but no clear
correlation was noted between the onset of the adverse
events and the dexmedetomidine concentration in
plasma.
Twenty of the 53 adverse events, reported in seven
of the 13 subjects, were classified as serious adverse
events. Five of the serious adverse events led to
death, with three of the deaths occurring during the
study-drug infusion period and leading to disconti-
nuation of the study treatment. The causes of the
deaths were chronic pulmonary disease (n =2 ) ,s e p -
sis, myocardial infarction with a myocardial rupture,
and pancreatitis.
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Figure 3 Dexmedetomidine concentration profiles during the 12-hour constant-rate infusion (n = 13) and the 48-hour follow-up after
stopping the infusion (n = 10). The infusion rate was 0.7 μg/kg/h in all but one patient, who received dexmedetomidine, 0.1 μg/kg/h (dashed
line), during the constant-rate phase. Conc, concentration.
Table 2 Characteristics and pharmacokinetic parameters of dexmedetomidine infusions in 13 intensive care patients
Patient number
Variable 1234567891 01 1 1 2 1 3 Mean CV (%)
Rate of the 12-h initial infusion (μg/kg/h) 0.1 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.6
a 58.1
Maximum infusion rate (μg/kg/h) 0.1 2.1 2.5 2.5 2.5 2.5 2.5 0.95 0.7 2.5 1.2 2.5 2.5 1.5
a 117
Length of infusion (h) 40 142 137 88 55 304 137 30 121 330 13 72 192 92.0
a 117
Cumulative dose (mg) 0.34 11 25 8.7 8.0 56 17 1.4 2.4 82 1.1 13 46 21.0 120
AUC0-∞ (ng h/ml) 17.8 376 550 174 252 924 337 39.0 100 1,530 29.7 350 583 213
a 233
Extrapolated fraction of AUC0-∞ (%) 1.3 0.1 0.0 0.1 22.0 0.0 0.0 0.6 0.2 0.0 37.1 9.3 0.0
t1/2 (h) 4.5 4.2 2.9 5.0 - 2.4 3.4 3.3 6.9 5.1 - - 2.1 3.7
a 38.1
Cl (L/h) 18.9 30.4 45.4 50.4 31.8 60.7 51.5 35.5 23.7 53.7 36.1 36.7 79.0 39.7
a 40.9
V (L) 123 184 193 362 - 213 252 170 234 391 - - 234 223
a 35.3
Because of missing samples for subjects 5, 11, and 12, it was not possible to define the elimination-phase parameters for these subjects, and the area under the
dexmedetomidine concentration-time curve extrapolated to infinity (AUC0-∞) was estimated by using the mean elimination half-life of the other patients. Subject
5 received hemodiafiltration. Cl, plasma clearance; CV, coefficient of variation; t1/2, elimination half-life; V, volume of distribution during elimination;
ageometric
mean (backtransformed mean of the values on the logarithmic scale).
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A strong linear relation was found between the area
under the dexmedetomidine concentration-time curve
and the cumulative dexmedetomidine dose in critically
ill patients. This suggests that the pharmacokinetics of
dexmedetomidine is linear at least up to the dose of 2.5
μg/kg/h, even in this very sick patient population, with
mean SAPS II of 44.8 (range, 22 to 73). This characteris-
tic means that when the dose of dexmedetomidine is
increased, its concentrations increase in a linear manner
with consequent potential pharmacologic effects [13].
Previous studies assessing the pharmacokinetics of
dexmedetomidine have involved mostly healthy subjects
[2,14,15]. One previous report exists on the pharmacoki-
netics of dexmedetomidine during ICU treatment in
postoperative coronary artery bypass patients, but the
dose in that study was limited to a maximum of 0.7 μg/
kg/h, and the mean duration of treatment was 10 hours
(range, 6 to 16 hours) [6]. The elimination half-life of
dexmedetomidine after the long duration of treatment
in our patients was comparable but still somewhat
longer than reported previously for dexmedetomidine
infusion of shorter duration and in healthier patients or
volunteers [2,6,15]. However, the values for dexmedeto-
midine clearance and volume of distribution were simi-
lar. The slower elimination of dexmedetomidine, as
judged by means of the elimination half-life, may be due
to the critical condition of our patients.
In one patient, the concentration of dexmedetomidine
(Figure 2) increased exceptionally during the 24-hour
period before her death from 3.4 to 9.9 ng/ml, with no
signs of liver dysfunction. She had paralytic ileus and
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Figure 4 Dexmedetomidine clearance at 116 steady states defined by a 15-hour constant-rate infusion in 12 subjects. Open triangles,
open circles, and solid circles indicate an infusion rate of 0.1, 0.4 to 2.1, and 2.5 μg/kg/h, respectively. Each line represents one patient. In two
patients, only one steady state was achieved, and the corresponding clearances are depicted with a single symbol.
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Figure 5 Relation of the total dexmedetomidine dose and the
area under the dexmedetomidine concentration-time curve
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Page 7 of 10severe septic shock, and her cardiac index was very low
(0.4 to 1.3 L/min/m
2) during her last day of life. Her
postmortem examination revealed myocardial infarction
with a rupture of the myocardium and hemopericar-
dium to be the direct causes of death. According to pre-
vious studies [3,16], the clearance of dexmedetomidine
may depend on hepatic blood flow. In this case, it can
be reasoned that dexmedetomidine concentration
increased exceptionally because of the impaired liver
blood flow.
AC l ss could be calculated on 116 occasions during
dexmedetomidine infusions. Although the rate of infu-
sion was statistically significantly associated to Clss in
multivariate analysis, it is unlikely that dexmedetomidine
would exhibit nonlinear pharmacokinetics. The increase
in dexmedetomidine Clss with the rate of infusion may
be related to improvement of the general condition of
the patients; that is, the sickest patients with poor liver
flow are more likely to need low doses. When a patient
is getting better with time with a simultaneous increase
of the liver blood flow and improvement of dexmedeto-
midine clearance, he/she needs more sedative agents,
thus giving the false impression of an association
between dexmedetomidine clearance and the dose.
One of the secondary objectives of the study was to
evaluate the patient factors that affect the pharmacoki-
netics of dexmedetomidine. The mean dexmedetomidine
clearance was statistically significantly higher, and the
mean elimination t1/2 statistically significantly shorter in
subjects with a baseline SAPS II score < 42, as com-
pared with the subjects with baseline SAPS II score >
42. In addition, a linear correlation appeared between
dexmedetomidine clearance and baseline creatinine
clearance. This may suggest a relation between the gen-
eral condition of the patient and lower dexmedetomi-
dine clearance, because renal function itself does not
affect pharmacokinetics of dexmedetomidine [17]. None
of the other patient factors that we evaluated signifi-
cantly affected the pharmacokinetic parameters of dex-
medetomidine. Hemodiafiltration was performed on one
subject during the study. No evidence was noted in this
single subject that dexmedetomidine was extracted from
plasma by hemodiafiltration. This finding must be con-
firmed in further studies.
The geometric mean value of the t1/2 of H-3 metabo-
lite was 9.05 hours, which is longer than that of the par-
ent dexmedetomidine, and the geometric mean ratio of
AUC0-∞ of H-3 metabolite to that of dexmedetomidine
was 1.47 (105%). However, the affinity of the H-3 meta-
bolite for a-2 receptors is less than 0.5% that of dexme-
detomidine (data on file) and therefore is not expected
to have clinically significant pharmacologic effects at
clinically relevant dexmedetomidine doses.
In this study, the patients were administered dexme-
detomidine to achieve a predefined level of sedation. A
significantly higher dose than described in the summary
information provided by the manufacturer was allowed,
and doses up to a maximum rate of 2.5 μg/kg/h were
administered to most of the patients. Indeed, approxi-
mately 70% of the entire study duration was spent at
the highest dose range (1.4 to 2.5 μg/kg/h). This dosing
regimen provided mostly adequate sedation, although
practically all patients received also additional propofol
(dose range, 79 to 8,505 mg/day). However, for two of
the three patients receiving the highest doses of addi-
tional propofol, the RASS target was amended to -4 for
most of the study duration, indicating that they required
deeper sedation. The high propofol use in these patients
is in accordance with earlier studies, which indicated
that dexmedetomidine alone may not be sufficient in
patients requiring deep levels of sedation [18].
Surprisingly, tachycardia was the most common
adverse event reported after start of the study treatment,
even though dexmedetomidine is well known to cause
bradycardia. However, tachycardia is common in ICU
patients [19], and the incidence of tachycardia and bra-
dycardia depend on the definition of them. Nevertheless,
we do not believe that dexmedetomidine per se induces
tachycardia.
Four adverse events were assessed to be related to the
study treatment. These included three incidents of bra-
dycardia and one episode of first-degree AV block. Dex-
medetomidine has been shown to have significant
effects on cardiac conduction in pediatric patients, pos-
sibly related to a decrease of sympathetic tone in the
CNS and/or a reflex response to the systemic vasocon-
striction caused by dexmedetomidine [20].
There have been inconsistent results in previous stu-
dies on the effect of dexmedetomidine dose on the inci-
dence of adverse events. Some studies suggest that
higher doses of dexmedetomidine may result in a higher
incidence of hypotension or bradycardia, whereas some
studies suggest the opposite [21]. In our study, most of
the adverse events during the study treatment were
recorded at the highest dose level (> 1.4 to 2.5 μg/kg/h),
but no clear correlation was seen between the onset of
the adverse events and the dexmedetomidine concentra-
tion in plasma. This finding was to be expected, because
most of the study duration was spent at this highest
dose range, and most adverse events were likely related
to the underlying critical illness. However, the effect of
dexmedetomidine dose on the incidence of adverse
events must be confirmed in future studies. Serious
adverse events seen in this study were typical of criti-
cally ill patients, and none of them was considered
related to dexmedetomidine.
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Page 8 of 10This study has several limitations. The small number
of patients limits further generalization of the results.
Patients having severe hepatic impairment (bilirubin >
101 μmol/L) were not considered eligible for the study,
and therefore, the results cannot be extrapolated to
patients with severe hepatic dysfunction. Although we
excluded also patients with uncompensated circulatory
failure at screening, many of the patients developed var-
ious circulatory problems during the study. Some of the
observed variability in the pharmacokinetics of dexme-
detomidine may thus be related to reduction in liver
blood flow.
Conclusions
This study describes the pharmacokinetics of high-dose
dexmedetomidine in a critically ill long-stay ICU patient
population. The results suggest that dexmedetomidine
obeys linear pharmacokinetics up to the dose of 2.5 μg/
kg/h, and dexmedetomidine clearance is lower in
patients with high baseline SAPS II scores than in those
with low SAPS II scores. Despite the high dosing regi-
men and prolonged infusions, no new safety findings
were found for dexmedetomidine.
Key messages
￿ Dexmedetomidine appears to have linear pharma-
cokinetics up to the dose of 2.5 μg/kg/h.
￿ Dexmedetomidine clearance is lower in patients
with high baseline SAPS II scores than in those with
low SAPS II scores.
￿ Despite the high dosing regimen and prolonged
infusions, no new safety findings were noted for
dexmedetomidine.
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